Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free PLRX Stock Alerts

Pliant Therapeutics (PLRX) Financials

Pliant Therapeutics logo
$1.09 +0.01 (+0.93%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$1.09 0.00 (0.00%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Pliant Therapeutics

Annual Income Statements for Pliant Therapeutics

This table shows Pliant Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -6.86 -42 -97 -123 -161 -210
Consolidated Net Income / (Loss)		 -0.63 -42 -97 -123 -161 -210
Net Income / (Loss) Continuing Operations		 -59 -42 -97 -123 -161 -210
Total Pre-Tax Income 		-60 -42 -97 -123 -161 -210
Total Operating Income		 -1.23 -42 -98 -127 -184 -228
Total Gross Profit		 57 42 7.57 9.69 1.58 0.00
Total Revenue		 57 42 7.57 9.69 1.58 0.00
Operating Revenue		 57 42 7.57 9.69 1.58 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 117 83 105 137 186 228
Selling, General & Admin Expense		 11 17 28 40 58 59
Research & Development Expense		 47 66 78 97 128 169
Total Other Income / (Expense), net		 0.00 0.00 0.27 3.88 23 18
Interest Expense		 - - -0.27 -3.88 -23 -18
Basic Earnings per Share		 ($4.22) ($1.95) ($2.71) ($2.94) ($2.75) ($3.47)
Weighted Average Basic Shares Outstanding		 1.62M 21.34M 35.85M 42.02M 58.72M 60.54M
Diluted Earnings per Share		 ($4.22) ($1.95) ($2.71) ($2.94) ($2.75) ($3.47)
Weighted Average Diluted Shares Outstanding		 1.62M 21.34M 35.85M 42.02M 58.72M 60.54M
Weighted Average Basic & Diluted Shares Outstanding		 - 35.74M 36.11M 58.94M 60.24M 61.24M
Cash Dividends to Common per Share		 - - $0.00 - $0.00 $0.00

Quarterly Income Statements for Pliant Therapeutics

This table shows Pliant Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -41 -41 -47 -56 -58 -51 -56 -43 -26 -20
Consolidated Net Income / (Loss)		 -41 -41 -47 -56 -58 -50 -56 -43 -26 -20
Net Income / (Loss) Continuing Operations		 -41 -41 -47 -56 -58 -50 -56 -43 -26 -20
Total Pre-Tax Income 		-41 -41 -47 -56 -58 -50 -56 -43 -26 -20
Total Operating Income		 -48 -47 -52 -61 -62 -53 -59 -46 -28 -22
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Operating Expenses		 48 47 52 61 62 53 59 46 28 22
Selling, General & Admin Expense		 15 14 15 15 14 15 15 13 10 8.19
Research & Development Expense		 32 33 37 46 48 39 43 32 18 14
Total Other Income / (Expense), net		 6.20 5.93 5.44 4.79 4.25 3.59 2.77 2.29 1.97 1.73
Interest Expense		 -6.20 -5.93 -5.44 -4.79 -4.25 -3.59 -2.77 -2.29 -1.97 -1.73
Basic Earnings per Share		 ($0.70) ($0.68) ($0.78) ($0.92) ($0.95) ($0.82) ($0.92) ($0.71) ($0.43) ($0.32)
Weighted Average Basic Shares Outstanding		 59.69M 58.72M 60.18M 60.38M 60.73M 60.54M 61.22M 61.39M 61.41M 61.80M
Diluted Earnings per Share		 ($0.70) ($0.68) ($0.78) ($0.92) ($0.95) ($0.82) ($0.92) ($0.71) ($0.43) ($0.32)
Weighted Average Diluted Shares Outstanding		 59.69M 58.72M 60.18M 60.38M 60.73M 60.54M 61.22M 61.39M 61.41M 61.80M
Weighted Average Basic & Diluted Shares Outstanding		 59.90M 60.24M 60.33M 60.80M 60.85M 61.24M 61.39M 61.39M 61.45M 61.92M
Cash Dividends to Common per Share		 - - $0.00 - - - $0.00 - - $0.00

Annual Cash Flow Statements for Pliant Therapeutics

This table details how cash moves in and out of Pliant Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 25 -35 0.78 -18 31 7.95
Net Cash From Operating Activities		 -2.75 -37 -75 -95 -116 -156
Net Cash From Continuing Operating Activities		 -2.75 -37 -75 -95 -116 -156
Net Income / (Loss) Continuing Operations		 -0.63 -42 -97 -123 -161 -210
Consolidated Net Income / (Loss)		 -0.63 -42 -97 -123 -161 -210
Depreciation Expense		 1.11 1.31 1.54 1.82 1.84 2.13
Amortization Expense		 - - 1.26 -1.81 -4.99 2.51
Non-Cash Adjustments To Reconcile Net Income		 1.83 4.16 12 22 47 41
Changes in Operating Assets and Liabilities, net		 -5.06 -1.21 6.92 6.48 1.25 9.09
Net Cash From Investing Activities		 -18 -211 74 -150 -127 140
Net Cash From Continuing Investing Activities		 -18 -211 74 -150 -127 140
Purchase of Property, Plant & Equipment		 -0.96 -1.53 -1.95 -1.76 -0.92 -3.85
Purchase of Investments		 -52 -323 -220 -326 -583 -211
Sale and/or Maturity of Investments		 35 113 296 177 457 355
Net Cash From Financing Activities		 46 213 2.53 227 274 23
Net Cash From Continuing Financing Activities		 46 213 2.53 227 274 23
Issuance of Debt		 - - 0.00 9.85 0.00 20
Issuance of Common Equity		 0.00 161 2.98 218 275 3.21
Other Financing Activities, net		 0.17 0.44 -0.46 -0.56 -0.85 0.00
Cash Interest Paid		 - - 0.00 0.62 1.15 2.62

Quarterly Cash Flow Statements for Pliant Therapeutics

This table details how cash moves in and out of Pliant Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Change in Cash & Equivalents		 2.73 7.04 51 -34 -0.77 -8.43 21 -5.12 6.91 -23
Net Cash From Operating Activities		 -36 -25 -30 -45 -32 -48 -49 -41 -21 -19
Net Cash From Continuing Operating Activities		 -36 -25 -30 -45 -32 -48 -49 -41 -21 -19
Net Income / (Loss) Continuing Operations		 -41 -41 -47 -56 -58 -50 -56 -43 -26 -20
Consolidated Net Income / (Loss)		 -41 -41 -47 -56 -58 -50 -56 -43 -26 -20
Depreciation Expense		 0.45 0.46 0.51 0.62 0.53 0.46 0.45 0.45 0.44 0.26
Amortization Expense		 -3.70 5.23 1.09 -0.15 1.00 0.57 1.36 1.98 0.34 0.42
Non-Cash Adjustments To Reconcile Net Income		 11 9.71 10 12 9.71 9.23 9.64 7.28 7.20 5.00
Changes in Operating Assets and Liabilities, net		 -2.44 0.61 4.73 -1.71 14 -8.18 -4.14 -7.01 -2.75 -4.87
Net Cash From Investing Activities		 38 32 60 11 31 39 69 35 28 -4.10
Net Cash From Continuing Investing Activities		 38 32 60 11 31 39 69 35 28 -4.10
Purchase of Property, Plant & Equipment		 -0.09 -0.06 -1.49 -1.25 -0.90 -0.21 -0.26 -0.11 - 0.00
Purchase of Investments		 -114 -57 -52 -49 -77 -33 -14 -52 -53 -65
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - 0.10
Sale and/or Maturity of Investments		 153 89 113 60 109 73 84 87 80 61
Net Cash From Financing Activities		 0.70 0.22 22 0.68 0.54 0.10 0.50 - 0.07 0.07
Net Cash From Continuing Financing Activities		 0.70 0.22 22 0.68 0.54 0.10 0.50 - 0.07 0.07
Issuance of Common Equity		 0.77 0.23 1.88 0.68 0.54 0.10 0.50 - 0.07 0.07
Cash Interest Paid		 0.29 0.29 0.50 0.54 0.81 0.77 0.72 0.73 0.74 0.00

Annual Balance Sheets for Pliant Therapeutics

This table presents Pliant Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 119 296 221 351 512 397 225
Total Current Assets		 112 291 209 340 506 362 196
Cash & Equivalents		 86 51 52 34 63 71 45
Short-Term Investments		 17 226 149 298 431 285 145
Prepaid Expenses		 1.74 4.50 6.76 7.06 11 6.54 4.46
Other Current Nonoperating Assets		 - - - - - - 1.04
Plant, Property, & Equipment, net		 4.08 4.32 4.61 4.49 3.57 5.53 2.94
Total Noncurrent Assets		 3.09 0.45 7.17 5.82 3.09 29 26
Other Noncurrent Operating Assets		 3.09 0.45 7.17 5.82 3.09 29 26
Total Liabilities & Shareholders' Equity		 119 296 221 351 512 397 225
Total Liabilities		 9.08 12 22 37 39 93 44
Total Current Liabilities		 8.17 12 17 24 29 33 16
Accounts Payable		 1.25 2.02 2.97 1.58 4.53 5.96 0.48
Accrued Expenses		 6.92 9.58 12 20 23 27 14
Other Current Liabilities		 - - 1.87 2.46 1.32 0.54 1.45
Total Noncurrent Liabilities		 0.91 0.87 5.33 13 10 60 28
Long-Term Debt		 - - 0.00 9.93 10 30 0.00
Other Noncurrent Operating Liabilities		 0.91 0.87 5.33 3.43 0.00 29 28
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -76 283 199 313 474 304 181
Total Preferred & Common Equity		 -76 283 199 313 474 304 181
Preferred Stock		 0.00 - - 0.00 0.00 0.00 0.00
Total Common Equity		 -76 283 199 313 474 304 181
Common Stock		 0.00 401 414 654 973 1,014 1,041
Retained Earnings		 -76 -118 -215 -338 -500 -710 -859
Accumulated Other Comprehensive Income / (Loss)		 -0.00 -0.03 -0.20 -1.96 0.35 0.32 -0.02

Quarterly Balance Sheets for Pliant Therapeutics

This table presents Pliant Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 540 522 484 446 345 300 277 203
Total Current Assets		 534 490 448 410 311 267 246 175
Cash & Equivalents		 58 114 80 80 92 87 94 22
Short-Term Investments		 466 368 356 325 214 176 148 149
Prepaid Expenses		 11 7.51 11 5.52 5.55 4.57 3.79 3.13
Other Current Nonoperating Assets		 - - - - - - - 0.91
Plant, Property, & Equipment, net		 3.97 5.61 5.40 5.67 5.24 4.89 4.34 2.66
Total Noncurrent Assets		 2.16 26 31 30 28 27 27 25
Other Noncurrent Operating Assets		 2.16 26 31 30 28 27 27 25
Total Liabilities & Shareholders' Equity		 540 522 484 446 345 300 277 203
Total Liabilities		 37 84 91 100 88 80 76 37
Total Current Liabilities		 27 30 31 40 28 21 18 10
Accounts Payable		 3.36 7.33 3.25 6.89 5.62 1.38 0.49 0.36
Accrued Expenses		 22 22 28 33 22 18 16 8.28
Other Current Liabilities		 2.06 0.77 0.10 0.32 0.77 1.23 1.19 1.71
Total Noncurrent Liabilities		 10 54 60 60 59 59 59 27
Long-Term Debt		 10 30 30 30 30 30 30 0.00
Other Noncurrent Operating Liabilities		 0.00 24 30 30 29 29 28 27
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 503 437 393 346 257 220 200 165
Total Preferred & Common Equity		 503 437 393 346 257 220 200 165
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 503 437 393 346 257 220 200 165
Common Stock		 964 985 996 1,005 1,023 1,030 1,036 1,045
Retained Earnings		 -459 -547 -603 -660 -766 -810 -836 -879
Accumulated Other Comprehensive Income / (Loss)		 -1.91 -0.49 -0.62 0.85 0.16 -0.00 0.03 -0.34

Annual Metrics And Ratios for Pliant Therapeutics

This table displays calculated financial ratios and metrics derived from Pliant Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% -26.70% -81.89% 27.91% -83.69% -100.00%
EBITDA Growth		 0.00% -34,082.20% -134.88% -34.25% -47.26% -19.45%
EBIT Growth		 0.00% -3,283.02% -134.21% -30.41% -44.77% -24.01%
NOPAT Growth		 0.00% -3,283.02% -134.21% -30.41% -44.77% -24.01%
Net Income Growth		 0.00% -6,482.09% -134.18% -26.79% -30.83% -30.35%
EPS Growth		 0.00% 53.79% -38.97% -8.49% 6.46% -26.18%
Operating Cash Flow Growth		 0.00% -1,255.31% -102.42% -25.43% -22.96% -33.64%
Free Cash Flow Firm Growth		 0.00% 0.00% -115.47% -36.47% -52.67% -18.09%
Invested Capital Growth		 0.00% -14.43% -124.92% -415.03% -34.10% -101.90%
Revenue Q/Q Growth		 0.00% 0.00% -24.57% -0.35% -55.43% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -4.70% -12.94% -1.55% -5.15%
EBIT Q/Q Growth		 0.00% 0.00% -6.07% -11.19% -5.52% -2.83%
NOPAT Q/Q Growth		 0.00% 0.00% -6.07% -11.19% -5.52% -2.83%
Net Income Q/Q Growth		 0.00% 0.00% -6.00% -9.33% -3.90% -4.28%
EPS Q/Q Growth		 0.00% 0.00% -27.83% -0.34% 0.36% -4.20%
Operating Cash Flow Q/Q Growth		 0.00% -333.56% -4.69% -13.66% 5.01% -16.97%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -22.76% -0.99% -8.43%
Invested Capital Q/Q Growth		 0.00% 0.00% -154.47% 40.69% -0.68% 24.94%
Profitability Metrics		 - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 -0.21% -96.46% -1,251.16% -1,313.20% -11,854.05% 0.00%
Operating Margin		 -2.16% -99.59% -1,288.10% -1,313.37% -11,654.75% 0.00%
EBIT Margin		 -2.16% -99.59% -1,288.10% -1,313.37% -11,654.75% 0.00%
Profit (Net Income) Margin		 -1.11% -99.32% -1,284.51% -1,273.32% -10,211.14% 0.00%
Tax Burden Percent		 1.06% 99.73% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 4,834.61% 100.00% 99.72% 96.95% 87.61% 92.09%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -11.96% -435.94% -2,949.22% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -12.18% -429.42% -2,937.08% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 11.38% 414.81% 2,908.87% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -0.57% -21.13% -40.35% -48.13% -41.00% -54.09%
Cash Return on Invested Capital (CROIC)		 0.00% -420.39% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -1.03% -20.09% -37.75% -44.49% -42.69% 0.00%
Return on Assets (ROA)		 -0.53% -20.04% -37.64% -43.13% -37.40% 0.00%
Return on Common Equity (ROCE)		 0.40% -11.12% -40.35% -48.13% -41.00% -54.09%
Return on Equity Simple (ROE_SIMPLE)		 0.83% -14.67% -48.86% -39.36% -34.07% -69.16%
Net Operating Profit after Tax (NOPAT)		 -0.86 -29 -68 -89 -129 -160
NOPAT Margin		 -1.51% -69.71% -901.67% -919.36% -8,158.32% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.22% -6.52% -12.14% -13.14% -8.05% -12.46%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -27.54% -26.65% -47.82%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 19.16% 41.30% 363.95% 412.48% 3,666.33% 0.00%
R&D to Revenue		 83.00% 158.29% 1,024.15% 1,000.89% 8,088.42% 0.00%
Operating Expenses to Revenue		 204.32% 199.59% 1,388.10% 1,413.37% 11,754.75% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.23 -42 -98 -127 -184 -228
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.12 -40 -95 -127 -187 -224
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 2.85 2.44 3.01 2.29 2.64
Price to Tangible Book Value (P/TBV)		 0.00 2.85 2.44 3.01 2.29 2.64
Price to Revenue (P/Rev)		 2.52 19.28 64.25 97.32 686.53 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 31.57 85.81 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 3.99 12.66 37.76 64.15 380.08 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.03 0.02 0.10
Long-Term Debt to Equity		 0.00 0.00 0.00 0.03 0.02 0.10
Financial Leverage		 -0.93 -0.97 -0.99 -1.02 -1.02 -1.04
Leverage Ratio		 1.08 1.05 1.07 1.12 1.10 1.17
Compound Leverage Factor		 52.34 1.05 1.07 1.08 0.96 1.08
Debt to Total Capital		 0.00% 0.00% 0.00% 3.07% 2.08% 9.04%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 3.07% 2.08% 9.04%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 169.37% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -69.37% 100.00% 100.00% 96.93% 97.92% 90.96%
Debt to EBITDA		 0.00 0.00 0.00 -0.08 -0.05 -0.14
Net Debt to EBITDA		 0.00 0.00 0.00 2.53 2.59 1.45
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.08 -0.05 -0.14
Debt to NOPAT		 0.00 0.00 0.00 -0.11 -0.08 -0.19
Net Debt to NOPAT		 0.00 0.00 0.00 3.61 3.76 2.04
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.11 -0.08 -0.19
Altman Z-Score		 10.10 39.05 11.44 13.74 15.44 1.77
Noncontrolling Interest Sharing Ratio		 169.37% 47.39% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 13.69 25.07 12.44 14.23 17.72 10.91
Quick Ratio		 13.44 24.67 12.04 13.93 17.33 10.71
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -28 -61 -83 -126 -149
Operating Cash Flow to CapEx		 -285.27% -2,432.83% -3,862.93% -5,376.76% -12,634.20% -4,041.14%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.48 0.20 0.03 0.03 0.00 0.00
Accounts Receivable Turnover		 8.09 5.12 1.34 4.87 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 13.99 9.96 1.70 2.13 0.39 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 45.12 71.27 271.80 75.02 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 45.12 71.27 271.80 75.02 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 7.21 6.17 -1.54 -7.92 -11 -21
Invested Capital Turnover		 7.92 6.25 3.27 -2.05 -0.17 0.00
Increase / (Decrease) in Invested Capital		 0.00 -1.04 -7.70 -6.38 -2.70 -11
Enterprise Value (EV)		 228 529 286 621 601 476
Market Capitalization		 144 806 487 943 1,085 801
Book Value per Share		 ($47.00) $7.98 $5.52 $6.43 $7.91 $5.00
Tangible Book Value per Share		 ($47.00) $7.98 $5.52 $6.43 $7.91 $5.00
Total Capital		 110 283 199 323 484 334
Total Debt		 0.00 0.00 0.00 9.93 10 30
Total Long-Term Debt		 0.00 0.00 0.00 9.93 10 30
Net Debt		 -103 -277 -201 -321 -484 -326
Capital Expenditures (CapEx)		 0.96 1.53 1.95 1.76 0.92 3.85
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.96 2.26 -7.99 -15 -17 -27
Debt-free Net Working Capital (DFNWC)		 104 279 193 316 477 329
Net Working Capital (NWC)		 104 279 193 316 477 329
Net Nonoperating Expense (NNE)		 -0.23 12 29 34 32 50
Net Nonoperating Obligations (NNO)		 -103 -277 -201 -321 -484 -326
Total Depreciation and Amortization (D&A)		 1.11 1.31 2.80 0.02 -3.15 4.64
Debt-free, Cash-free Net Working Capital to Revenue		 1.67% 5.41% -105.47% -152.70% -1,092.85% 0.00%
Debt-free Net Working Capital to Revenue		 181.81% 667.56% 2,543.71% 3,266.89% 30,188.48% 0.00%
Net Working Capital to Revenue		 181.81% 667.56% 2,543.71% 3,266.89% 30,188.48% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.95) ($2.71) ($2.94) ($2.75) ($3.47)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 21.34M 35.85M 42.02M 58.72M 60.54M
Adjusted Diluted Earnings per Share		 $0.00 ($1.95) ($2.71) ($2.94) ($2.75) ($3.47)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 21.34M 35.85M 42.02M 58.72M 60.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 35.74M 36.11M 58.94M 60.24M 61.24M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.86 -29 -68 -89 -129 -160
Normalized NOPAT Margin		 -1.51% -69.71% -901.67% -919.36% -8,158.32% 0.00%
Pre Tax Income Margin		 -104.32% -99.59% -1,284.51% -1,273.32% -10,211.14% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -409.19% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Pliant Therapeutics

This table displays calculated financial ratios and metrics derived from Pliant Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
DEI Shares Outstanding		 59,834,098.00 59,895,958.00 59,895,958.00 60,325,832.00 60,801,425.00 - 61,236,291.00 61,386,278.00 61,388,154.00 61,449,385.00
DEI Adjusted Shares Outstanding		 59,834,098.00 59,895,958.00 59,895,958.00 60,325,832.00 60,801,425.00 - 61,236,291.00 61,386,278.00 61,388,154.00 61,449,385.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.69 -0.68 -0.78 -0.93 -0.95 - -0.92 -0.71 -0.43 -0.33
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -58.20% -7.43% -14.83% -18.48% -18.73% -26.48% -12.48% 28.25% 54.53% 63.08%
EBIT Growth		 -49.26% -25.77% -24.46% -28.13% -30.05% -13.36% -12.49% 24.81% 54.42% 63.06%
NOPAT Growth		 -49.26% -25.77% -24.46% -28.13% -30.05% -13.36% -12.49% 24.81% 54.42% 63.06%
Net Income Growth		 -35.51% -17.25% -25.05% -35.59% -39.23% -20.98% -19.62% 22.48% 54.47% 64.32%
EPS Growth		 -7.69% 1.45% -16.42% -31.43% -35.71% -20.59% -17.95% 22.83% 54.74% 65.22%
Operating Cash Flow Growth		 -95.83% 19.65% 0.02% -82.95% 10.91% -89.87% -61.42% 10.36% 34.68% 60.65%
Free Cash Flow Firm Growth		 -276.13% -52.65% 5.13% -50.93% 29.80% 12.31% -40.87% 18.07% -46.80% 29.67%
Invested Capital Growth		 21.01% -34.10% -176.95% -14.48% -170.81% -101.90% -20.87% 10.30% 61.29% 63.55%
Revenue Q/Q Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -0.32% 18.83% -22.83% -18.46% -0.53% 13.53% -9.23% 24.43% 36.30% 0.00%
EBIT Q/Q Growth		 -0.75% 1.36% -11.38% -15.74% -2.27% 14.02% -10.53% 22.64% 38.00% 0.00%
NOPAT Q/Q Growth		 -0.75% 1.36% -11.38% -15.74% -2.27% 14.02% -10.53% 22.64% 38.00% 0.00%
Net Income Q/Q Growth		 -0.72% 0.91% -14.22% -18.95% -3.42% 13.90% -12.94% 22.91% 39.26% 0.00%
EPS Q/Q Growth		 0.00% 2.86% -14.71% -17.95% -3.26% 13.68% -12.20% 22.83% 39.44% 0.00%
Operating Cash Flow Q/Q Growth		 -46.31% 30.70% -20.59% -49.64% 28.75% -47.68% -2.52% 16.91% 48.08% 0.00%
Free Cash Flow Firm Q/Q Growth		 -34.20% 16.46% 10.49% -50.41% 37.58% -4.36% -43.78% 12.52% -11.83% 0.00%
Invested Capital Q/Q Growth		 12.91% -0.68% -41.83% 7.94% -106.02% 24.94% 15.09% 31.69% 11.09% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 87.00% 87.40% 89.62% 92.11% 93.15% 93.27% 95.30% 94.97% 93.04% 92.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -36.97% -41.00% -34.17% -40.06% -47.52% -54.09% -63.22% -67.55% -64.27% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -36.97% -41.00% -34.17% -40.06% -47.52% -54.09% -63.22% -67.55% -64.27% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -30.87% 0.00% -39.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -33 -33 -37 -42 -43 -37 -41 -32 -20 -15
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.88% -2.03% -2.02% -2.82% -3.23% -3.06% -4.10% -3.56% -2.22% -2.15%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.81% -7.85% -10.04% -11.55% -11.17% -14.35% -12.74% -8.58% -9.23%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -48 -47 -52 -61 -62 -53 -59 -46 -28 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -51 -41 -51 -60 -60 -52 -57 -43 -27 -21
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.06 2.29 2.04 1.65 1.97 2.64 0.32 0.32 0.45 0.47
Price to Tangible Book Value (P/TBV)		 2.06 2.29 2.04 1.65 1.97 2.64 0.32 0.32 0.45 0.47
Price to Revenue (P/Rev)		 292.67 686.53 3,598.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 147.79 380.08 1,774.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.02 0.02 0.07 0.08 0.09 0.10 0.12 0.14 0.15 0.00
Long-Term Debt to Equity		 0.02 0.02 0.07 0.08 0.09 0.10 0.12 0.14 0.15 0.00
Financial Leverage		 -1.03 -1.02 -1.02 -1.03 -1.05 -1.04 -1.05 -1.04 -1.07 -1.06
Leverage Ratio		 1.09 1.10 1.12 1.14 1.16 1.17 1.25 1.28 1.32 1.30
Compound Leverage Factor		 0.95 0.96 1.00 1.05 1.08 1.09 1.19 1.21 1.23 1.19
Debt to Total Capital		 1.95% 2.08% 6.42% 7.11% 8.02% 9.04% 10.54% 12.12% 13.19% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.95% 2.08% 6.42% 7.11% 8.02% 9.04% 10.54% 12.12% 13.19% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 98.05% 97.92% 93.58% 92.89% 91.98% 90.96% 89.46% 87.88% 86.81% 100.00%
Debt to EBITDA		 -0.05 -0.05 -0.15 -0.15 -0.14 -0.14 -0.13 -0.14 -0.17 0.00
Net Debt to EBITDA		 2.78 2.59 2.33 2.00 1.76 1.45 1.20 1.09 1.17 0.00
Long-Term Debt to EBITDA		 -0.05 -0.05 -0.15 -0.15 -0.14 -0.14 -0.13 -0.14 -0.17 0.00
Debt to NOPAT		 -0.08 -0.08 -0.22 -0.21 -0.19 -0.19 -0.18 -0.20 -0.23 0.00
Net Debt to NOPAT		 4.20 3.76 3.32 2.80 2.41 2.04 1.67 1.51 1.62 0.00
Long-Term Debt to NOPAT		 -0.08 -0.08 -0.22 -0.21 -0.19 -0.19 -0.18 -0.20 -0.23 0.00
Altman Z-Score		 16.29 16.32 5.61 3.15 2.56 3.23 -2.12 -2.76 -2.86 -4.22
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 19.50 17.72 16.12 14.47 10.26 10.91 11.03 12.99 13.93 16.89
Quick Ratio		 19.11 17.33 15.87 14.12 10.13 10.71 10.84 12.77 13.72 16.50
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -36 -30 -27 -41 -25 -27 -38 -33 -37 -27
Operating Cash Flow to CapEx		 -38,536.17% -41,150.82% -2,028.89% -3,620.86% -3,601.90% -22,804.78% -18,650.38% -36,252.68% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.81 0.39 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -11 -11 -15 -14 -29 -21 -18 -12 -11 -6.63
Invested Capital Turnover		 -0.30 -0.17 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 2.80 -2.70 -9.62 -1.75 -18 -11 -3.14 1.43 18 12
Enterprise Value (EV)		 524 601 440 242 307 476 -193 -161 -121 -93
Market Capitalization		 1,038 1,085 892 649 682 801 83 71 91 77
Book Value per Share		 $8.41 $7.91 $7.27 $6.51 $5.69 $5.00 $4.20 $3.59 $3.26 $2.67
Tangible Book Value per Share		 $8.41 $7.91 $7.27 $6.51 $5.69 $5.00 $4.20 $3.59 $3.26 $2.67
Total Capital		 513 484 467 423 376 334 287 250 231 165
Total Debt		 10 10 30 30 30 30 30 30 30 0.00
Total Long-Term Debt		 10 10 30 30 30 30 30 30 30 0.00
Net Debt		 -514 -484 -452 -407 -374 -326 -275 -233 -211 -171
Capital Expenditures (CapEx)		 0.09 0.06 1.49 1.25 0.90 0.21 0.26 0.11 0.00 -0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -17 -17 -23 -20 -34 -27 -23 -16 -14 -6.32
Debt-free Net Working Capital (DFNWC)		 507 477 460 417 370 329 283 247 228 165
Net Working Capital (NWC)		 507 477 460 417 370 329 283 247 228 165
Net Nonoperating Expense (NNE)		 8.11 8.18 10 13 14 12 15 11 6.51 4.80
Net Nonoperating Obligations (NNO)		 -514 -484 -452 -407 -374 -326 -275 -233 -211 -172
Total Depreciation and Amortization (D&A)		 -3.26 5.69 1.60 0.48 1.53 1.02 1.81 2.42 0.77 0.68
Debt-free, Cash-free Net Working Capital to Revenue		 -470.30% -1,092.85% -9,226.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 14,300.14% 30,188.48% 185,285.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 14,300.14% 30,188.48% 185,285.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.70) ($0.68) ($0.78) ($0.92) ($0.95) ($0.82) ($0.92) ($0.71) ($0.43) ($0.32)
Adjusted Weighted Average Basic Shares Outstanding		 59.69M 58.72M 60.18M 60.38M 60.73M 60.54M 61.22M 61.39M 61.41M 61.80M
Adjusted Diluted Earnings per Share		 ($0.70) ($0.68) ($0.78) ($0.92) ($0.95) ($0.82) ($0.92) ($0.71) ($0.43) ($0.32)
Adjusted Weighted Average Diluted Shares Outstanding		 59.69M 58.72M 60.18M 60.38M 60.73M 60.54M 61.22M 61.39M 61.41M 61.80M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 59.90M 60.24M 60.33M 60.80M 60.85M 61.24M 61.39M 61.39M 61.45M 61.92M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -33 -37 -42 -43 -37 -41 -32 -20 -15
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Pliant Therapeutics (NASDAQ: PLRX) continues to operate as a pre-revenue biotech with a large cash balance, but the latest quarter shows the company burning cash and moving toward a leaner balance sheet. Across the last several years, the big picture is consistent: no product revenue, ongoing operating losses, and heavy reliance on cash, investments, and equity financing to fund research and development.

  • PLRX still has a meaningful liquidity cushion. As of Q1 2026, the company held $22.2 million in cash and equivalents plus $148.7 million in short-term investments, for total current assets of $174.9 million.
  • Debt appears manageable, with no long-term debt in the latest quarter. Long-term debt was reported at $0 in Q1 2026, down from $30.4 million in Q3 2025.
  • Investments remain a major source of liquidity. In Q1 2026, PLRX sold or matured $60.7 million of investments, helping offset operating losses and fund the business.
  • Share count has not shown explosive dilution recently. Basic shares outstanding were 61.8 million in Q1 2026, only modestly above the 60.5 million range seen in late 2024 and 2025.
  • The company continues to spend heavily on R&D. Q1 2026 research and development expense was $13.6 million, reflecting the ongoing cost of clinical-stage development.
  • Operating expense discipline improved versus prior quarters. Total operating expenses fell to $21.8 million in Q1 2026 from $28.3 million in Q3 2025 and $45.6 million in Q2 2025.
  • Interest expense is lower than it was last year. Interest expense was $1.7 million in Q1 2026 versus $2.0 million in Q3 2025 and $4.8 million in Q2 2025.
  • PLRX remains deeply unprofitable. The company posted a Q1 2026 net loss of $20.0 million, or $(0.32) per share, with no revenue and no gross profit.
  • Operating cash flow is still negative. Q1 2026 operating cash outflow was $19.2 million, showing the business continues to consume cash at a substantial rate.
  • The balance sheet has shrunk significantly from a year earlier. Total assets fell to $202.6 million in Q1 2026 from $445.7 million in Q3 2024 and $521.6 million in Q1 2024, mainly because cash and investments declined as the company funded operations.

Longer-term trend: PLRX has been steadily drawing down its investment portfolio and cash since early 2024. Total current assets fell from $489.9 million in Q1 2024 to $174.9 million in Q1 2026. At the same time, retained earnings have worsened to a cumulative deficit of $879.4 million, underscoring the scale of accumulated losses.

Bottom line: Pliant Therapeutics still has enough cash and marketable investments to operate in the near term, but the company remains a high-burn, pre-revenue biotech. Investors should focus on cash runway, clinical progress, and whether management can preserve capital while advancing its pipeline.

07/25/26 08:55 PM ETAI Generated. May Contain Errors.

Pliant Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Pliant Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

Pliant Therapeutics' net income appears to be on an upward trend, with a most recent value of -$210.30 million in 2024, rising from -$631 thousand in 2019. The previous period was -$161.34 million in 2023. Check out Pliant Therapeutics' forecast to explore projected trends and price targets.

Pliant Therapeutics' total operating income in 2024 was -$228.37 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $228.37 million

Over the last 5 years, Pliant Therapeutics' total revenue changed from $57.05 million in 2019 to $0.00 in 2024, a change of -100.0%.

Pliant Therapeutics' total liabilities were at $44.02 million at the end of 2025, a 52.6% decrease from 2024, and a 384.6% increase since 2019.

In the past 6 years, Pliant Therapeutics' cash and equivalents has ranged from $33.69 million in 2022 to $85.81 million in 2019, and is currently $45.45 million as of their latest financial filing in 2025.

Over the last 5 years, Pliant Therapeutics' book value per share changed from -47.00 in 2019 to 5.00 in 2024, a change of -110.6%.


Related Companies

Financial statements for NASDAQ:PLRX last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel